Natural cytotoxicity receptors and their ligands

Immunology and Cell Biology

Volumn 92, Issue 3, 2014, Pages 221-229

  Kruse, Philip H ^a,b   Matta, Jessica ^a,b   Ugolini, Sophie ^a,b   Vivier, Eric ^a,b,c  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b INSERM   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

Author keywords

cancer; ILC; innate immunity; natural cytotoxicity receptor; NK cell; virus

Indexed keywords

B7 H6 PROTEIN; CELLULAR LIGAND; CYCLINE; CYTOMEGALOVIRUS ANTIGEN PP65; HEMAGGLUTININ; HEPARAN SULFATE; HLA B ASSOCIATED TRANSCRIPT 3; HN PROTEIN; LIGAND; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NKP44L PROTEIN; UNCLASSIFIED DRUG;

BACTERIUM; FLAVIVIRUS; HUMAN; IMMUNOCYTOTOXICITY; NATURAL KILLER CELL; NONHUMAN; PARASITE; PROTEIN FUNCTION; REVIEW; VIRUS;

BACTERIA (MICROORGANISMS);

ANIMALS; BACTERIA; HUMANS; LIGANDS; MODELS, IMMUNOLOGICAL; PARASITES; RECEPTORS, NATURAL CYTOTOXICITY TRIGGERING; VIRUSES;

EID: 84899004889     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.98     Document Type: Review

References (100)

1. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975; 16: 216-229.
2. Kiessling R, Klein E, Wigzell H. 'Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975; 5: 112-117.
3. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9: 503-510.
4. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science 2004; 306: 1517-1519.
5. Kä rre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 1986; 319: 675-678.
6. Lanier LL. NK Cell Recognition. Annu Rev Immunol 2005; 23: 225-274.
7. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31: 413-441.
8. Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997; 186: 1129-1136.
9. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J ExpMed 1998; 187: 2065-2072.
10. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999; 190: 1505-1516.
11. Byrd A, Hoffmann SC, Jarahian M, Momburg F, Watzl C. Expression Analysis of the ligands for the natural killer cell receptors NKp30 and NKp44. PLoS ONE 2007; 2: e1339.
12. Castriconi R, Dondero A, Augugliaro R, Cantoni C, Carnemolla B, Sementa AR et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA 2004; 101: 12640-12645.
13. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002; 62: 6178-6186.
14. Joyce MG, Sun PD. The structural basis of ligand recognition by natural killer cell receptors. J Biomed Biotechnol 2011; 2011: 203628.
15. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006; 18: 151-158.
16. Yu J, Mitsui T, Wei M, Mao H, Butchar JP, Shah MV et al. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. J Clin Invest 2011; 121: 1456-1470.
17. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13: 145-149.
18. Meresse B, Curran SA, Ciszewski C, Orbelyan G, Setty M, Bhagat G et al. Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med 2006; 203: 1343-1355.
19. Ponassi M, Cantoni C, Biassoni R, Conte R, Spallarossa A, Pesce A et al. Structure of the human NK cell triggering receptor NKp46 ectodomain. Biochem Biophys Res Commun 2003; 309: 317-323.
20. Foster CE, Colonna M, Sun PD. Crystal structure of the human NK cell activating receptor NKp46 reveals structural relationship to other leukocyte receptor complex immunoreceptors. J Biol Chem 2003; 278: 46081-46086.
21. Jaron-Mendelson M, Yossef R, Appel MY, Zilka A, Hadad U, Afergan F et al. Dimerization of NKp46 receptor is essential for NKp46-mediated lysis: characterization of the dimerization site by epitope mapping. J Immunol 2012; 188: 6165-6174.
22. Narni-Mancinelli E, Jaeger BN, Bernat C, Fenis A, Kung S, De Gassart A et al. Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses. Science 2012; 335: 344-348.
23. Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, Malaspina A et al. NKp44, A triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999; 189: 787-796.
24. Demaria A, Ugolotti E, Rutjens E, Mazza S, Radic L, Faravelli A et al. NKp44 expression, phylogenesis and function in non-human primate NK cells. Int Immunol 2009; 21: 245-255.
25. Allcock RJ, Barrow AD, Forbes S, Beck S, Trowsdale J. The human TREM gene cluster at 6p21.1 encodes both activating and inhibitory single IgV domain receptors and includes NKp44. Eur J Immunol 2003; 33: 567-577.
26. Cantoni C, Ponassi M, Biassoni R, Conte R, Spallarossa A, Moretta A et al. The threedimensional structure of the human NK cell receptor NKp44, a triggering partner in natural cytotoxicity. Structure 2003; 11: 725-734.
27. Campbell KS, Yusa S, Kikuchi-Maki A, Catina TL. NKp44 triggers NK cell activation through DAP12 association that is not influenced by a putative cytoplasmic inhibitory sequence. J Immunol 2004; 172: 899-906.
28. Rosental B, Brusilovsky M, Hadad U, Oz D, Appel MY, Afergan F et al. Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol 2011; 187: 5693-5702.
29. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Ann Rev Immunol 2001; 19: 197-223.
30. Vacca P, Cantoni C, Prato C, Fulcheri E, Moretta A, Moretta L et al. Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction between NK cells and trophoblast cells. Evidence for divergent functional profiles of decidual versus peripheral NK cells. Int Immunol 2008; 20: 1395-1405.
31. Fuchs A, Cella M, Kondo T, Colonna M. Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. Blood 2005; 106: 2076-2082.
32. Tang Q, Grzywacz B, Wang H, Kataria N, Cao Q, Wagner JE et al. Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional. J Immunol 2008; 181: 4507-4515.
33. Correia DV, Fogli M, Hudspeth K, da Silva MG, Mavilio D, Silva-Santos B. Differentiation of human peripheral blood Vdelta1\+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 2011; 118: 992-1001.
34. Ponnampalam AP, Gargett CE, Rogers PA. Identification and hormonal regulation of a novel form of NKp30 in human endometrial epithelium. Eur J Immunol 2008; 38: 216-226.
35. Li Y, Wang Q, Mariuzza RA. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J Exp Med 2011; 208: 703-714.
36. Joyce MG, Tran P, Zhuravleva MA, Jaw J, Colonna M, Sun PD. Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site. Proc Natl Acad Sci USA 2011; 108: 6223-6228.
37. Neville MJ, Campbell RD. A new member of the Ig superfamily and a V-ATPase G subunit are among the predicted products of novel genes close to the TNF locus in the human MHC. J Immunol 1999; 162: 4745-4754.
38. Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17: 700-707.
39. Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother 1994; 9: 225-235.
40. Alsheikhly A, Orvell C, Harfast B, Andersson T, Perlmann P, Norrby E. Sendai-virusinduced cell-mediated cytotoxicity in vitro. The role of viral glycoproteins in cell-mediated cytotoxicity. Scand J Immunol 1983; 17: 129-138.
41. Alsheikhly AR, Orvell C, Andersson T, Perlmann P. The role of serologically defined epitopes on mumps virus HN-glycoprotein in the induction of virus-dependent cellmediated cytotoxicity. Analysis with monoclonal antibodies. Scand J Immunol 1985; 22: 529-538.
42. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409: 1055-1060.
43. Jarahian M, Watzl C, Fournier P, Arnold A, Djandji D, Zahedi S et al. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol 2009; 83: 8108-8121.
44. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 2001; 31: 2680-2689.
45. Chisholm SE, Reyburn HT. Recognition of vaccinia virus-infected cells by human natural killer cells depends on natural cytotoxicity receptors. J Virol 2006; 80: 2225-2233.
46. Jarahian M, Fiedler M, Cohnen A, Djandji D, Hammerling GJ, Gati C et al. Modulation of NKp30-and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog 2011; 7: e1002195.
47. Maisner A, Herrler G. Membrane cofactor protein with different types of N-glycans can serve as measles virus receptor. Virology 1995; 210: 479-481.
48. Arnon TI, Achdout H, Lieberman N, Gazit R, Gonen-Gross T, Katz G et al. The mechanisms controlling the recognition of tumor-and virus-infected cells by NKp46. Blood 2004; 103: 664-672.
49. Mendelson M, Tekoah Y, Zilka A, Gershoni-Yahalom O, Gazit R, Achdout H et al. NKp46 O-glycan sequences that are involved in the interaction with hemagglutinin type 1 of influenza virus. J Virol 2010; 84: 3789-3797.
50. Brown CK, Turner PC, Moyer RW. Molecular characterization of the vaccinia virus hemagglutinin gene. J Virol 1991; 65: 3598-3606.
51. Gazit R, Gruda R, Elboim M, Arnon TI, Katz G, Achdout H et al. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol 2006; 7: 517-523.
52. Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005; 6: 515-523.
53. Muller TF, Gicklhorn D, Jungraithmayr T, Eickmann M, Lange H, Radsak K et al. Pattern and persistence of the epitope-specific IgM response against human cytomegalovirus in renal transplant patients. J Clin Virol 2002; 24: 45-56.
54. Hershkovitz O, Rosental B, Rosenberg LA, Navarro-Sanchez ME, Jivov S, Zilka A et al. NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. J Immunol 2009; 183: 2610-2621.
55. Esin S, Batoni G, Pardini M, Favilli F, Bottai D, Maisetta G et al. Functional characterization of human natural killer cells responding to Mycobacterium bovis bacille Calmette-Guerin. Immunology 2004; 112: 143-152.
56. Esin S, Counoupas C, Aulicino A, Brancatisano FL, Maisetta G, Bottai D et al. Interaction of Mycobacterium tuberculosis cell wall components with the human natural killer cell receptors NKp44 and Toll-like receptor 2. Scand J Immunol 2013; 77: 460-469.
57. Esin S, Batoni G, Counoupas C, Stringaro A, Brancatisano FL, Colone M et al. Direct binding of human NK cell natural cytotoxicity receptor NKp44 to the surfaces of mycobacteria and other bacteria. Infect Immun 2008; 76: 1719-1727.
58. Garg A, Barnes PF, Porgador A, Roy S, Wu S, Nanda JS et al. Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor. J Immunol 2006; 177: 6192-6198.
59. Chaushu S, Wilensky A, Gur C, Shapira L, Elboim M, Halftek G et al. Direct recognition of Fusobacterium nucleatum by the NK cell natural cytotoxicity receptor NKp46 aggravates periodontal disease. PLoS Pathog 2012; 8: e1002601.
60. Mavoungou E, Held J, Mewono L, Kremsner PG. A duffy binding-like domain is involved in the NKp30-mediated recognition of Plasmodium falciparum- parasitized erythrocytes by natural killer cells. J Infect Dis 2007; 195: 1521-1531.
61. Baratin M, Roetynck S, Lepolard C, Falk C, Sawadogo S, Uematsu S et al. Natural killer cell and macrophage cooperation in MyD88-dependent innate responses to Plasmodium falciparum. Proc Natl Acad Sci USA 2005; 102: 14747-14752.
62. Baratin M, Roetynck S, Pouvelle B, Lemmers C, Viebig NK, Johansson S et al. Dissection of the role of PfEMP1 and ICAM-1 in the sensing of plasmodium falciparum-infected erythrocytes by natural killer cells. PLoS One 2007; 2: e228.
63. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195: 343-351.
64. Wehner R, Dietze K, Bachmann M, Schmitz M. The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun 2011; 3: 258-263.
65. Bialoszewska A, Baychelier F, Niderla-Bielinska J, Czop A, Debre P, Vieillard V et al. Constitutive expression of ligand for natural killer cell NKp44 receptor (NKp44L) by normal human articular chondrocytes. Cell Immunol 2013; 285: 6-9.
66. Poirot L, Benoist C, Mathis D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Acad Sci USA 2004; 101: 8102-8107.
67. Alba A, Planas R, Clemente X, Carrillo J, Ampudia R, Puertas MC et al. Natural killer cells are required for accelerated type 1 diabetes driven by interferon-beta. Clin Exp Immunol 2008; 151: 467-475.
68. Gur C, Enk J, Kassem SA, Suissa Y, Magenheim J, Stolovich-Rain M et al. Recognition and killing of human and murine pancreatic beta cells by the NK receptor NKp46. J Immunol 2011; 187: 3096-3103.
69. Gur C, Enk J, Weitman E, Bachar E, Suissa Y, Cohen G et al. The expression of the beta cell-derived autoimmune ligand for the killer receptor nkp46 is attenuated in type 2 diabetes. PLoS One 2013; 8: e74033.
70. Hecht ML, Rosental B, Horlacher T, Hershkovitz O, De Paz JL, Noti C et al. Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J Proteome Res 2009; 8: 712-720.
71. Hershkovitz O, Jarahian M, Zilka A, Bar-Ilan A, Landau G, Jivov S et al. Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. Glycobiology 2008; 18: 28-41.
72. Bloushtain N, Qimron U, Bar-Ilan A, Hershkovitz O, Gazit R, Fima E et al. Membraneassociated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol 2004; 173: 2392-2401.
73. Warren HS, Jones AL, Freeman C, Bettadapura J, Parish CR. Evidence that the cellular ligand for the human NK Cell activation receptor NKp30 is not a heparan sulfate glycosaminoglycan. J Immunol 2005; 175: 207-212.
74. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 2009; 11: 615-628.
75. Stoimenov I, Helleday T. PCNA on the crossroad of cancer. Biochem Soc Trans 2009; 37: 605-613.
76. Naryzhny SN, Lee H. Characterization of proliferating cell nuclear antigen (PCNA) isoforms in normal and cancer cells: there is no cancer-associated form of PCNA. FEBS letters 2007; 581: 4917-4920.
77. Krishna TS, Kong XP, Gary S, Burgers PM, Kuriyan J. Crystal structure of the eukaryotic DNA polymerase processivity factor PCNA. Cell 1994; 79: 1233-1243.
78. Garzetti GG, Ciavattini A, Goteri G, Tranquilli AL, Muzzioli M, Fabris N et al. Natural killer cell activity in stage I endometrial carcinoma: correlation with nuclear grading, myometrial invasion, and immunoreactivity of proliferating cell nuclear antigen. Gynecol Oncol 1994; 55: 111-114.
79. Horton NC, Mathew SO, Mathew PA. Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44. PLoS One 2013; 8: e59552.
80. Korgun ET, Celik-Ozenci C, Acar N, Cayli S, Desoye G, Demir R. Location of cell cycle regulators cyclin B1, cyclin A, PCNA, Ki67 and cell cycle inhibitors p21, p27 and p57 in human first trimester placenta and deciduas. Histochem Cell Biol 2006; 125: 615-624.
81. Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debre P, Vieillard V. Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood 2013; 9: 225-235.
82. Deng LW, Chiu I, Strominger JL. MLL 5 protein forms intranuclear foci, and overexpression inhibits cell cycle progression. Proc Natl Acad Sci USA 2004; 101: 757-762.
83. Cheng F, Liu J, Zhou SH, Wang XN, Chew JF, Deng LW. RNA interference against mixed lineage leukemia 5 resulted in cell cycle arrest. Int J Biochem Cell Biol 2008; 40: 2472-2481.
84. Vieillard V, Strominger JL, Debre P. NK cytotoxicity against CD4\+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc Natl Acad Sci USA 2005; 102: 10981-10986.
85. Vieillard V, Habib RE, Brochard P, Delache B, Bovendo HF, Calvo J et al. CCR5 or CXCR4 use influences the relationship between CD4 cell depletion, NKp44L expression and NK cytotoxicity in SHIV-infected macaques. Aids 2008; 22: 185-192.
86. Fausther-Bovendo H, Sol-Foulon N, Candotti D, Agut H, Schwartz O, Debre P et al. HIV escape from natural killer cytotoxicity: Nef inhibits NKp44L expression on CD4\+ T cells. Aids 2009; 23: 1077-1087.
87. Ward J, Bonaparte M, Sacks J, Guterman J, Fogli M, Mavilio D et al. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood 2007; 23: 1077-1087.
88. Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007; 27: 965-974.
89. Binici J, Hartmann J, Herrmann J, Schreiber C, Beyer S, Guler G et al. A soluble fragment of the tumor antigen BCL2-associated athanogene 6 (BAG-6) is essential and sufficient for inhibition of NKp30-dependent cytotoxicity of natural killer cells. J Biol Chem 2013; 23: 1077-1087.
90. Wu W, Song W, Li S, Ouyang S, Fok KL, Diao R et al. Regulation of apoptosis by Bat3-enhanced YWK-II/APLP2 protein stability. J Cell Sci 2012; 125: 4219-4229.
91. Desmots F, Russell HR, Michel D, McKinnon PJ. Scythe regulates apoptosis-inducing factor stability during endoplasmic reticulum stress-induced apoptosis. J Biol Chem 2008; 283: 3264-3271.
92. Desmots F, Russell HR, Lee Y, Boyd K, McKinnon PJ. The reaper-binding protein scythe modulates apoptosis and proliferation during mammalian development. Mol Cell Biol 2005; 25: 10329-10337.
93. Wu YH, Shih SF, Lin JY. Ricin triggers apoptotic morphological changes through caspase-3 cleavage of BAT3. J Biol Chem 2004; 279: 19264-19275.
94. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206: 1495-1503.
95. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8: 467-477.
96. Kaifu T, Escaliere B, Gastinel LN, Vivier E, Baratin M. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life Sci 2011; 68: 3531-3539.
97. Hartmann J, Tran TV, Kaudeer J, Oberle K, Herrmann J, Quagliano I et al. The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding. J Biol Chem 2012; 287: 31527-31539.
98. Matta J, Baratin M, Chiche L, Forel JM, Cognet C, Thomas G et al. Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood 2013; 122: 394-404.
99. Rusakiewicz S, Nocturne G, Lazure T, Semeraro M, Flament C, Caillat-Zucman S et al. NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Sci Transl Med 2013; 5: 195ra96.
100. Hudspeth K, Silva-Santos B, Mavilio D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol 2013; 4: 69.